The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Waldenström’s Macroglobulinemia venetoclax therapy
Jorge Castillo
• 13 Sep 2019
Jorge Castillo, MD Dana-Farber Cancer Institute, Boston, MA, provides an update on phase II trials of venetoclax therapy as a treatment for Waldenström’s Macroglobulinemia patients, alongside an overview of the disease biology. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
